Get to know our clinical trials
Trial of BMI-F106C plus nivolumab vs. nivolumab in HLA A*02:01-positive participants with previously untreated advanced melanoma.
THE MAIN OBJECTIVE OF THIS STUDY IS TO KNOW WHETHER THE STUDY DRUG (IMC-F106C AT TWO DIFFERENT DOSES) IN COMBINATION WITH THE REFERENCE TREATMENT (NIVOLUMAB) IS BETTER THAN NIVOLUMAB ALONE IN KEEPING TUMORS FROM INCREASING OR DECREASING IN SIZE.
Technical Summary
- RANDOMIZED, CONTROLLED PHASE III STUDY OF IMC-F106C PLUS NIVOLUMAB VERSUS NIVOLUMAB REGIMENS IN HLA A*02:01-POSITIVE PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA IMMUNOTHERAPY
- Code EudraCT: 2023-505306-42-00
- Protocol number: IMC-F106C-301
- Promoter: Immunocore Ltd.
- Molecule/Drug: IMC-F106C
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.